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Introduction 
 
Heparin is commonly used in many clinical scenarios, 
including venous thromboembolism, acute coronary 
syndromes, atrial fibrillation, orthopedic surgeries, 
dialysis, during extracorporeal circulation and 
peripheral occlusive disease.1 A life-threatening 
complication following heparin therapy is heparin-
induced thrombocytopenia (HIT). Generally, there are 
two types of HIT. Type 1 HIT is a mild and non-
immune disorder that presents early, usually in the 
first 48 hours after exposure to heparin. It is caused by 
an interaction between heparin and platelets leading to 
the formation of platelet aggregates.1,2 Type 2 HIT is 
an immune-mediated condition which occurs 4-14 
days after exposure and sometimes has life-
threatening complications.2 HIT has many different 
manifestations, so it is important to be cautious in a 
patient who is on heparin for any reason. Here, we are 
reporting a case of an elderly lady presented with 
frank hematuria (a rare presentation) later diagnosed 
as HIT and ultimately had extensive renal vein 
thrombosis which led to end-organ damage. 
 
Case Presentation  
 
A 76 years old female known case of knee 
osteoarthritis for the last 8 years, had bilateral knee 
replacement one week back due to chronic debilitating 
osteoarthritis. Before her surgery complete blood 
count was normal with platelet count 234200/μL. 
After surgery, the patient was started on low-
molecular-weight heparin (LMWH) 5000 IU twice 
daily as thromboprophylaxis. The patient was 
borderline diabetic and her sugar levels were 
controlled with dietary restrictions. She presented to 
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our hospital with frank hematuria and mild left-sided 
lumbar pain. Her platelet count of 234200/μL fell to 
16000/μL by the sixth postoperative day. Blood 
pressure was 118/69 mmHg with a pulse of 89 beats 
per minute. She was afebrile and was maintaining 
oxygen saturation of 100%. All relevant investigations 
were performed (Table 1).  
 
Table 1: Laboratory Results 
Test Result Normal Range 
Hemoglobin 9.6    g/dL  11.5-14.5 g/dL 
White blood 
cells count 
9010   /μL 4000-11000/μL  
Neutrophils 55%  50-70%  
Lymphocytes  22% 20-40% 
Monocytes 6% 2-10% 
Eosinophils 0.0% 0-6% 
Platelets count 16000 /μL 150000- 
450000/μL 
Prothrombin 
time 
14.4  seconds 11.5-14.5 seconds 
Activated 
partial 
thromboplastin 
time 
45.00 
seconds 
30-41 seconds 
International 
normalized 
ratio 
1.1 0.9-1.3 
Retics  % 4.0% 0.5%-2.5% 
ESR 79 0-15 mm/hour 
Hemolysis Screen: Negative  
Autoimmune Profile: Negative 
Malignancy Screen: Negative 
Molecular Genetic Analysis for BCR-ABL p-210 
expression…Negative 
 
Table 2: Hematology Screening 
Test Result Normal Range 
Protein C  0.82  0.7-1.4 u/mL 
Anti-thrombin III 
(ATIII) 
0.96 0.80-1.20 u/mL 
Factor V Leiden  
APC Resistence  
300 120-300 Sec 
Plasminogen  0.91 0.75-1.4 iu/mL 
Procalcitonin 
(Endocrionology) 
1.09 ng/mL 
 
Heparin was stopped immediately. She was 
transfused with 10 units of platelets. The patient's 
consultant considered sepsis leading to disseminated 
intravascular coagulation and accelerated platelet 
removal from circulation. Despite more platelet 
transfusion, the platelet count after eight days was 
30100/μL. She underwent a CT abdomen which 
showed left renal vein thrombosis. At this point, HIT 
seemed very likely so the next day treating physician 
ordered a heparin-platelet factor 4 enzyme-linked 
immunosorbent assay (ELISA) which proved strongly 
positive and showed 96% inhibition with heparin. On 
peripheral film, there were no schistocytes and all 
relevant investigations were done to rule 
out TTP/HUS which were negative. Further, CT 
abdomen with contrast showed left renal vein 
thrombosis, hepatic vein thrombosis and partial 
thrombosis in the portal vein (Figure 1). 
 
Figure 1: CT scan abdomen showing thrombus and 
infarction in left kidney 
 
The patient was started on intravenous argatroban 
which is a direct thrombin inhibitor and later shifted to 
oral rivaroxaban after 10 days. All other possibilities 
were ruled out. She was being monitored as an in-
patient with daily INR and PT/APTT results. 
Hematuria and lumbar pain settled and the patient 
started improving clinically. Two weeks later when 
she was ready to be discharged from the hospital, she 
complained of bilateral lower limb pain. On 
examination, limbs were swollen and Doppler 
ultrasound showed echogenic thrombus in common 
femoral, superficial femoral and common iliac 
veins. Her platelet count was in the normal range at 
that time and there was no evidence of active 
thrombosis at other sites. The common femoral and 
iliac veins were non-compressible with no flow 
detected as shown on Doppler (Figure 2). 
 
95                                                                                   Journal of Rawalpindi Medical College (JRMC); 2020; 24(1): 93-96  
 
Figure 2: Doppler ultrasound showing DVT in left 
lower limb 
 
The patient was again switched to intravenous 
argatroban keeping in view the high risk of thrombosis 
in other parts of the body. The next day, after 
discussing with an interventional radiologist, the 
patient underwent inferior vena cava (IVC) filter 
insertion to prevent any further catastrophic event. A 
week later, magnetic resonance imaging (MRI) showed 
persistent partial occlusion of left renal vein, left-sided 
infarcted kidney with some viable parenchyma and 
interval recanalization of the right hepatic vein. 
Laboratory parameters showed acute kidney injury 
with creatinine reaching 2.1 mg/dl and later falling to 
1.0 mg/dl after one week. The patient was discharged 
on oral rivaroxaban and advised to have a close 
follow-up as an outpatient. 
 
Discussion 
 
Heparin-induced thrombocytopenia is a paradoxical 
prothrombotic state leading to widespread thrombosis 
causing complications like pulmonary embolism, 
mesenteric ischemia, ischemic limb necrosis, stroke, 
and acute myocardial infarction. These thrombotic 
complications are life-threatening in about 29% of 
patients, and an additional 21% have to undergo limb 
amputations. Some of the alarming signs pointing 
towards HIT may include a rash at the injection site, 
fever associated with rigors and chills, dyspnea and 
chest pain. HIT should be strongly considered as a 
differential diagnosis in case of platelet count 
dropping to less than 50 % of the baseline count. 
The main culprit in the pathophysiology of HIT is 
antibodies against PF4 and heparin. In a study, 
Rauova and colleagues claimed that heparin and PF4 
form ultra-large (>670kDa) complexes which are made 
up of multiple PF4 tetramers and several molecules 
of unfractionated heparin (UFH).3 Interestingly the 
number of these complexes is way too small when 
factor Xa inhibitors are used instead of UFH. The 
antibodies bind to these complexes on the surface 
of platelets and induce platelet activation by cross-
linking FcγIIA receptors.4,5 The activated platelets 
exhibit more surface expression for PF4, creating 
positive feedback and further release of PF4 promoting 
further platelet activation. Platelet activation results in 
the release of microparticles which are procoagulants 
that further cause platelet consumption. Marked 
release of thrombin, activation of monocytes and 
endothelial injury produce characteristic venous and 
arterial thrombosis of HIT. 
Thrombocytopenia in elderly patients receiving 
heparin has a high association with the development 
of thrombotic events. Women diagnosed with HIT are 
1.7 times more likely to develop a thrombotic event. In 
a retrospective study, there were 408 patients 
diagnosed with HIT out of which 66 % were older than 
60 years. About 10% of patients needed 
amputation and 20% were reported to suffer from 
other associated morbid conditions. 
The ‘4T's’ scoring system can be used as a guide to 
identifying patients who are at risk for developing 
HIT.6,7 Heparin should be immediately discontinued 
once HIT is suspected. Blood samples should be taken 
to confirm the diagnosis. HIT screening is now 
available in many standard laboratories. 
Unfractionated heparin (UFH) poses a ten-fold 
increased risk of causing HIT as compared to low 
molecular weight heparin (LMWH). A study 
conducted by Smythe and colleagues revealed that the 
incidence of HIT in patients receiving intravenous 
UFH for therapeutic doses was 0.76%, whereas the 
percentage dropped down to less than 0.1 in 
patients receiving subcutaneous UFH for prophylaxis. 
Alternative anticoagulation in the form of argatroban, 
lepirudin, danaparoid, and rivaroxaban can be used. 
The duration of the treatment with new agents 
mentioned is not well-defined. However, it should be 
continued for 2-3 months to prevent recurrent 
thrombosis. These drugs are direct inhibitors of 
thrombin and/or factor Xa inhibitors.8 They also 
inhibit thrombin-induced reactions, including fibrin 
formation, activation of various coagulation factors 
and platelet aggregation. Its use should be regularly 
monitored with the activated partial thromboplastin 
time (aPTT) or activated clotting time (at higher levels 
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of anticoagulation) for argatroban, ecarin clotting time 
(ECT) for lepirudin, and anti‐Xa assays for 
danaparoid.9 The use of warfarin is not advised until 
platelet count has fully recovered. Prophylactic 
platelet transfusion is not recommended as well as it 
can exacerbate the hypercoagulable state leading to 
additional thrombosis. Sometimes, the benefit of 
antithrombotic drugs is partially offset by hemorrhagic 
complications. The estimated incidence of major 
bleeding is higher with lepirudin (13-19%) than 
argatroban (6-7%). 
 
Conclusion 
  
This case report highlights the significance of early 
diagnosis and prompt management of HIT as a late 
diagnosis can lead to disastrous complications. The 
prolonged use of heparin for postoperative 
thromboprophylaxis carries the highest risk of HIT. 
However, HIT can even develop with minimal heparin 
exposure via intravascular flushes used to maintain 
the patency of indwelling arterial or venous catheters. 
Use of LMWH or factor Xa inhibitors may be 
recommended for thromboprophylaxis instead of 
unfractionated heparin where applicable.  Bleeding is 
uncommon in HIT but still can be a presentation. New 
refined drugs like danaparoid, argatroban, lepirudin, 
and rivaroxaban can be used for anticoagulation in 
patients with HIT and have shown promising results. 
 
References 
 
1. Warkentin TE, Greinacher A. Heparin-induced 
thrombocytopenia: recognition, treatment, and prevention: the 
Seventh ACCP Conference on Antithrombotic and Thrombolytic 
Therapy. Chest. 2004 Sep 1;126(3):311S-37S. 
https://doi.org/10.1378/chest.126.3_suppl.311S  
2. Bui VC, Gebicka P, Hippe H, Raschke R, Nguyen TL, 
Greinacher A, Nguyen TH. Physicochemical Characteristics of 
Platelet Factor 4 under Various Conditions are Relevant for 
Heparin-Induced Thrombocytopenia Testing. The Journal of 
Physical Chemistry B. 2020 Jan 16. 
https://doi.org/10.1021/acs.jpcb.9b11695  
3. Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, 
Sachais BS, Poncz M. Heparin induced thrombocytopenia: an 
autoimmune disorder regulated through dynamic autoantigen 
assembly/disassembly. Journal of Clinical Apheresis: The Official 
Journal of the American Society for Apheresis. 2007 
Feb;22(1):31-6. https://doi.org/10.1002/jca.20109 
4. Gowthami M. Arepally: Heparin-induced thrombocytopenia. 
American Society of Hematology. 2017, 129 (10):2864-72.  
5. Warkentin TE. Clinical picture of heparin-induced 
thrombocytopenia (HIT) and its differentiation from non-HIT 
thrombocytopenia. Thrombosis and haemostasis. 2016 
Nov;116(11):813-22. DOI: 10.1160/TH16-06-0435 
6. Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, 
Trenor III CC. Pediatric heparin-induced thrombocytopenia: 
prevalence, thrombotic risk, and application of the 4Ts scoring 
system. The Journal of pediatrics. 2015 Jan 1;166(1):144-50. 
https://doi.org/10.1016/j.jpeds.2014.09.017  
7. Esther A. Obeng, Kathy M. Harney, Thomas Moniz, Alana 
Arnold, Ellis J. Neufeld, Cameron C. Trenor III: Predictive value of 
the 4Ts scoring system for heparin-induced thrombocytopenia: a 
systematic review and meta-analysis. Blood. Nov 2012, 
120:4160-4167.  
8. Miyares MA, Davis KA. Direct-acting oral anticoagulants as 
emerging treatment options for heparin-induced 
thrombocytopenia. Annals of Pharmacotherapy. 2015 
Jun;49(6):735-9. https://doi.org/10.1177/1060028015579424 
9. Skelley JW, Kyle JA, Roberts RA. Novel oral anticoagulants 
for heparin-induced thrombocytopenia. Journal of thrombosis 
and thrombolysis. 2016 Aug 1;42(2):172-8. 
